The earlier that cancer can be found, the higher the chance of survival. Cancers diagnosed in early stages have survival rates that are five to ten times higher compared with late stage diagnoses.1
For example, for breast cancer, the 5-year relative survival rate (meaning the percentage of people who live at least 5 years after being diagnosed with cancer) for people with stage I or stage II cancer is over 90%, compared to about 70% for stage III and 20% for stage IV.2
GRAIL, Inc., a healthcare company located in Menlo Park, CA, is using new technology to develop a blood test that can find small pieces of genomic material, such as DNA, released into the blood by cancer cells.
Cancers involve a change in the genes of the cells in one of the body’s organs or tissues. The change leads to abnormal growth causing a tumor mass. These tumor cells release small pieces of genomic material, such as DNA into the blood. This is referred to as cell-free nucleic acid (cfNA). Genomic sequencing involves the study of nucleic acid isolated from cells in the body. In this case, genomic sequencing of the cfNA from the blood sample is used to identify changes in the genes, in hopes of finding genomic material from tumors very early in the tumor’s growth.
To help GRAIL develop an effective blood test for early cancer detection, data from tens of thousands of people are needed. By participating in STRIVE, you are contributing your data to the large evidence base needed to support the development of a blood test that is designed to detect multiple cancer types.
Thank you for participating in a study that we hope will be instrumental in developing a new tool for early detection of cancer.
1Cho, H., Mariotto, A.B., Schwartz, L.M., Luo, J., and Woloshin, S. (2014). When do changes in cancer survival mean progress?
The insight from population incidence and mortality. J. Natl. Cancer Inst. – Monogr. 2014, 187–197.
Learn more about the STRIVE study on our FAQ page